ENZON PHARMACEUTICALS, INC. (ENZN)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenues | - | - | 26 | |
| General and administrative | 314 | 351 | 351 | |
| Transaction expenses | 1,219 | - | - | |
| Total operating expenses | 1,533 | 351 | 351 | |
| Operating loss | -1,533 | -351 | -325 | |
| Interest and dividend income | 501 | 654 | 605 | |
| (loss) income before income tax benefit (expense) | -1,032 | 303 | 280 | |
| Income tax benefit (expense) | -42 | 49 | 4 | |
| Net (loss) income | -990 | 254 | 276 | |
| Accretion of dividend on series c preferred stock | 531 | 531 | 531 | |
| Net loss available to common shareholders | -1,521 | -277 | -255 | |
| Earnings per share, basic | -0.02 | - | - | |
| Earnings per share, diluted | 74,215,000 | 74,215,000 | 74,215,000 | |
| Weighted average number of shares outstanding, basic | 74,215,000 | 74,215,000 | 74,215,000 | |
| Weighted average number of shares outstanding, diluted | -0.02 | - | - | |